To date, only a limited number of interventional studies—specifically three—have directly investigated the effects of MR blockade on human MASLD and its associated hepatic fibrosis [51,52,53]. The gene discussed is NR3C2; the disease is metabolic dysfunction-associated steatotic liver disease.